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Abstract—The bio-manufacturing of recombinant proteins 
from mammalian cell cultures requires robust processes that can 
maximize protein yield while ensuring the efficacy of these 
proteins as human therapeutics.   Recognizing that the challenge 
of improving protein yield and quality can be met through 
various approaches, this paper presents three strategies currently 
being developed in our group.  A method for rapidly selecting 
subpopulations of cells with high production characteristics is 
proposed.  This method combines the efficiency of green 
fluorescent protein/fluorescence-activated cell sorting 
(GFP/FACS)–based screening with homologous recombination to 
generate and select high-producing subclones.  Next, the 
development of chemically defined, protein-free media for 
enhancing monoclonal antibody production is described.  
Analysis of culture media effects on the genome-wide 
transcriptional program of the cell is presented as a means to 
optimize the culture media and identify potential targets for 
genetic manipulation.  Finally, we propose a method for 
increasing the extent of intracellular sialylation by improving the 
transport of CMP-sialic acid into the trans-Golgi.  This is 
hypothesized to increase the sialic acid availability, and may 
enhance the degree of sialylation in the glycoprotein product.   
 
Index Terms—Clonal Selection, Glycosylation, Mammalian 
Cell Culture, Media Design 
 
I. INTRODUCTION 
RECOMBINANT protein production using mammalian cells offers several advantages over microbial systems.  
For example, mammalian cells are able to secrete the protein 
product, hence, obviating the need for cell homogenization.  
Furthermore, they are able to perform post-translational 
modifications, like glycosylation, which are necessary for the 
efficacy of protein drugs targeted as human therapeutics.  
However, mammalian cells have significantly slower growth 
rates compared to microbes and are much more complex in 
their nutritional requirements.  To meet the demands of 
commercial production and regulatory requirements, bio-
manufacturers are faced with the challenge of maximizing 
productivity whilst controlling product quality.   
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Recognizing that the challenge of improving protein yield 
and quality can be met through various approaches, this paper 
describes three strategies currently being developed in our 
group.  Firstly, to generate cell lines that can produce high 
yields of recombinant proteins, a method for rapidly selecting 
high-producing mammalian cell clones following 
recombination with the gene of interest is proposed.  Apart 
from the productivity of a specific cell line, another factor that 
has significant impact on recombinant protein yield and 
quality is the culture media.  We describe our efforts to design 
a chemically defined, protein-free media for enhancing protein 
production.  In addition, the effects of culture media on gene 
expression are being studied to gain insights into the impact of 
the media environment on cell physiology.  Finally, as a 
potential method to improve the efficacy of recombinant 
proteins produced through cell culture, we put forth a proposal 
for enhancing the sialylation process in Chinese Hamster 
Ovary (CHO) cell lines.   
 
II. A GFP-BASED SCREEN FOR HIGH-PRODUCING CLONES 
A key step in the generation of cell lines producing 
recombinant proteins is the selection of viable clones 
following the incorporation of the gene of interest into the 
host cell.  For industrial-scale bioproduction, a clone in which 
the product gene is stably integrated and yields a high level of 
the protein product is highly desired.   
During the engineering of recombinant cell lines, the 
product gene is integrated together with a selection marker, 
which enables successfully transfected clones to be isolated 
from the population.  Resistance to antibiotics (e.g. neomycin 
gene encoding resistance to G418) or enzyme analogs (e.g. 
dihydrofolate reductase gene encoding methotrexate 
resistance) are two common types of selection markers.  
However, these selection markers have been shown to 
increase the metabolic burden on the cells, which leads to a 
reduction in cell growth [1, 2].  In a heterogeneous population, 
high-producing subclones are rare and would tend to be 
diluted out by the faster growing non- or low-producing cells.  
To overcome this problem, limited dilution methods have 
been used.  Since the integration of a recombinant gene into 
 
 
the host genome is a largely random event, the proportion of 
cells containing multiple copies of stably integrated genes 
would be small compared to those with low copy numbers.  
There is a significant probability that a random sample of the 
total number of transfected cells may not contain the highest, 
stable producer. Thus, to isolate a subclone with an increased 
production rate, many wells would need to be screened and 
tested.  In general, limited dilution methods are tedious and 
time consuming. 
To alleviate some of these problems, we propose a novel 
technique for selecting high-producing cell clones that uses 
the Green Fluorescent Protein (GFP) as a selection marker, 
coupled with sorting through a Fluorescence Activated Cell 
Sorter (FACS).  Fig. 1 shows a schematic of the proposed 
method.  The ease and efficiency of GFP/FACS-based  
screening methods had been demonstrated in previous studies 
[3, 4].  In these previous reports, GFP was incorporated as 
part of a fusion protein [5] or part of a bicistronic construct 
using either an internal ribosomal entry site (IRES) [6] or a 
two promoter system [3].  Cells with a high-level of GFP 
correlated with a high level of the protein product of interest.  
This can be attributed to the stable integration of a high 
number of copies of the recombinant gene or that the gene had 
been integrated into sites of very high transcriptional activity.  
Although these methods have been shown to be effective, 
there may be some concern regarding the use of GFP-
containing cell lines for the production of human therapeutics.  
Furthermore, it appears unnecessary to burden the cell’s 
metabolic machinery with GFP production after the 
subpopulation has been isolated.  This cellular resource could 
potentially be diverted to increasing cell growth or 
recombinant protein production.  With these in mind, we 
propose a modification of the GFP/FACS technique, as 
illustrated in Fig. 1.   
Initially, plasmid vectors containing the cDNA encoding for 
GFP are constructed.  In addition, known sequences flanking 
both sides of the GFP gene are included to facilitate 
subsequent homologous recombination and strand exchange.  
Cell transfected with the GFP-containing vector are then 
FACS sorted to screen for cells with high fluorescent 
intensity, which would correspond to high-producing 
subclones.  These subclones are subsequently subjected to 
homologous recombination, exchanging the GFP gene with 
the desired protein gene.  Cells that have successfully acquired 
the desired protein gene are then FACS selected by screening 
for cells with low fluorescent intensity.  Finally, the selected 
clones are expanded and tested for production and stability. 
As FACS enables a large number of cells to be easily 
screened, the chance of obtaining high producing clones 
would be greatly increased compared to limited dilution 
methods.  Moreover, the procedure is less labor-intensive and 
may significantly reduce the time required to generate clones 
for bioproduction. 
 
III. MEDIA DESIGN AND ITS EFFECTS ON GENE EXPRESSION 
The culture media has an important impact on both the 
yield and quality of recombinant proteins from mammalian 
cells.  Mammalian cells require a combination of both 
nutritive (e.g. sugars and amino acids) and non-nutritive (e.g. 
trace metals, vitamins and co-factors) components to support 
cell growth and protein production.  In addition, the media 
environment has been shown to affect protein glycosylation, 
which is an important aspect of protein quality and influences 
its efficacy as a therapeutic [7, 8].  
Traditionally, cell culture media were supplemented with 
serum, usually derived from fetal calves, to provide essential 
non-nutritive components as well as some nutritive 
compounds.  Although some industrial cultivation processes 
still rely on serum supplementation, newer processes are 
directing towards serum-reduced or serum-free culture media 
for technical and economic reasons.  For example, variability 
between serum lots can have a significant impact on culture 
performance.  Serum is also quite costly (>US$200/L).  These 
serum-free media usually consists of basal formulations 
fortified with insulin, transferrin, albumin and other protein 
materials, which are generally obtained from animal sources.  
However, there are concerns that these sources harbor 
potential adventitious contamination from animal-borne 
viruses or prions.  This has spurred efforts to design media 
with greater biochemical definition, free from animal-derived 
components.  In addition, the use of protein-free media may 
facilitate downstream purification, possibly simplifying the 
purification process or improving product recovery. 
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Fig. 1.  Schematic of novel technique for rapid selection of high-producing 
cell clones. 
Our current research focuses on improving protein 
production through the design of chemically-defined, protein-
free media.  Insulin is one of the most common protein 
supplements for serum-free formulations.  It is involved in a 
variety of cellular functions, including glycolysis, cell cycling 
and anti-apoptosis [9].  Previous work has shown that 
 
 
withdrawal of insulin leads to a reduction in viable cell 
density and viability [10].  As insulin is usually obtained from 
bovine pancreas, there is a potential risk of contamination 
from animal-borne viruses.  Some researchers have substituted 
bovine insulin with recombinant insulin produced in E. coli 
[11].  However, this still carries the risk of foreign protein 
contamination and is a relatively costly solution.  On the other 
hand, we have found that the insulin requirement can be 
effectively overcome by supplementing the media with the 
appropriate trace metals.  Working with the murine 
hybridoma, CRL 1606, we have demonstrated that the cells 
could proliferate in insulin-free media in the presence of a 
trace metal supplement, without the need for adaptation (Fig. 
2).  Furthermore, monoclonal antibody production was not 
adversely affected by the substitution (Fig. 3).  Studies to 
understand the insulin-mimetic qualities of these trace metals 
are currently in progress.  Additionally, the media formulation 
is being optimized to further increase monoclonal antibody 
production.  
Traditionally, most media formulations are generally 
derived through numerous empirical tests and is fairly time-
consuming.  A novel approach to tackle the problem of media 
design is to apply high-throughput analytical tools, such as the 
DNA microarray, to analyze the effects of various media 
conditions on a genome-wide level.  By understanding the 
genetic profile of the cells grown in different media, we can 
potentially identify “deficiencies” in the formulation, leading 
to a more rational approach to media design.  In addition, 
based on the transciptional profile, we can also select 
candidate genes that may be genetically manipulated to 
modify the nutritional requirements of the cells.  The potential 
for the latter application is illustrated by the work reported in 
[12], in which the authors obviated the requirement of a CHO 
cell line for basic fibroblast growth factor by overexpressing 
cyclin E. 
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Fig.  2.  Batch culture of the hybridomaCRL1606 in various media. 
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Fig.  3.  Antibody production of CRL1606 in various media. 
 
IV. IMPROVING SIALYLATION OF GLYCOPROTEINS 
The efficacy of recombinant glycoproteins as a human 
therapeutic is strongly dependent on their carbohydrate 
structures, or glycosylation [7].  Glycosylation has been 
implicated in bioactivity, receptor binding, susceptibility to 
proteolysis, immunogenicity and in vivo clearance rate [13].  
As an example, Fig. 4 shows the full N-linked glycan structure 
of interferon-γ produced in recombinant CHO cells.  Sialic 
acid (SA), the terminal sugar for N-linked glycosylation, plays 
a major role in a glycoprotein’s circulatory lifetime.  The 
presence of sialic acid can prevent recognition of the 
glycoprotein by asialoglycoprotein receptors and hence 
prolong its circulatory lifetime [14].  Therefore, for certain 
therapeutic functions, it is desirable to maximize the degree of 
sialylation of the glycoprotein to enhance its quality and 
efficacy.  Furthermore, regulatory authorities are increasing 
requirements for the control of the glycosylation 
characteristics of glycoproteins produced from cell culture 
processes. 
Sialylation is governed by two opposing processes: 
intracellular sialylation and extracellular desialylation.  
Extracellular desialylation is thought to be caused by 
sialadases released through cell lysis, especially during the 
later phase of cell culture.  Harvesting the product before 
extensive cell lysis occurs can readily reduce the extent of 
extracellular desialylation.  The use of sialidase antisense 
technology [15] or sialidase inhibitors [16] are other 
alternatives that have been reported.  On the other hand, 
improving intracellular sialylation is significantly more 
challenging.  Intracellular protein glycosylation is a tightly 
orchestrated chain of events; it requires the expression and 
 
 
subcellular localization of glycosyltransferases and 
glycosidases, the availability of intraluminal nucleotide sugar 
substrates, the streric accessibility of the glycosylation site for 
oligosaccharide processing and the transit time available for 
oligosaccharide formation [17].  There have been various 
attempts to improve intracellular sialylation through 
overexpression of sialytransferases [18, 19] or feeding of 
nucleotide sugars [2, 20, 21].  For example, Gu and Wang 
[17] fed up to 20 mM of N-acetylmannosamine (ManNAc), a 
sialic acid precursor, to CHO cells producing interferon-γ and 
observed an increase in percentage sialylation from 60 to 
80%.  However, no further improvement was observed with 
feeding of 40 mM ManNAc.  Similarly, overexpressing 
sialytransferases had only limited success in augmenting the 
extent of sialylation [18, 19].  These results suggest that, apart 
from sialic acid and sialytransferase availability, other 
processes may be limiting intracellular sialylation.  It is 
hypothesized that the transport of sialic acid into the trans-
Golgi via the sialic acid transporter may be the limiting factor 
which governs the rate of intracellular sialylation.  Fig. 5 
illustrates the sialylation mechanism in the Golgi.  Prior to 
sialylation, sialic acid is produced in the cytosol and 
subsequently activated with cytidine triphosphate to form 
cytidine monophosphate-sialic acid (CMP-sialic acid) in the 
nucleus.  CMP-sialic acid is then transported from the nucleus 
through the cytosol and into the trans-Golgi.  Once there, the 
sialic acid is added to the growing sugar chain by 
sialytransferases.  It is proposed that the availability of CMP-
sialic acid in the trans-Golgi is limited by its rate of transport 
through the sialic acid transporter (Fig. 5).  Thus, 
overexpressing the CMP-sialic acid transporters in the cells 
may potentially relieve the sialic acid limitation within the 
Golgi, thus increasing the degree of glycoprotein sialylation.  
Overexpression of the sialic acid transporters will need to be 
coupled with other strategies, such as the feeding of 
nucleotide sugar precursors (e.g. ManNAc) or overexpressing 
sialytransferase to further improve intracellular sialylation in 
the cells.  
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Fig. 4.  Biantennary N-linked glycan structure of interferon-γ produced from
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V. CONCLUSION 
 
In this paper, we outlined some of the strategies for 
improving the production of recombinant proteins from 
mammalian cells currently being pursued in our group.  
Whilst each of these have been described separately, there is a 
potential for integrating these strategies to engineer a robust, 
high-producing cell line growing in a chemically-defined 
media that is able to maximize the production of recombinant 
proteins with the right glycosylation qualities.  Such 
integrated strategies may become essential to satisfy the 
increasing demands for therapeutic proteins.   
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